Protagonist Therapeutics Presents Long-Term Follow-up Of Rusfertide Phase 2 REVIVE Study Open Label Extension At The EHA 2024 Congress
Portfolio Pulse from Benzinga Newsdesk
Protagonist Therapeutics announced additional data from the rusfertide Phase 2 REVIVE study will be presented at the EHA Congress in Madrid, Spain, June 13-16, 2024. The data includes a published abstract showing no QTc prolongation with rusfertide, based on a study in healthy subjects.
May 14, 2024 | 8:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Protagonist Therapeutics' announcement of presenting additional rusfertide Phase 2 REVIVE study data at the EHA Congress could positively impact investor sentiment, especially with the positive QTc prolongation data.
Presenting positive study results at a prestigious congress like EHA can significantly enhance a biotech company's reputation and investor confidence, especially when it concerns safety data like QTc prolongation absence. This could lead to increased investor interest and potentially a positive short-term impact on PTGX's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100